Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)

PA-16-152
Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)
Department of Health and Human Services
National Institutes of Health

investigatorinitiated-research-grants-at-the-nih-something-nih-12-638

Program Considerations

The duration of training, the transition of trainees to individual support mechanisms, and their progress to the next career stage are important considerations in institutional training programs.  Training PDs/PIs should limit appointments to individuals who are committed to a research career and who plan to remain in training for at least two years, whether that support comes from a training grant or some combination of NRSA and non-NRSA support programs.  Training PDs/PIs should encourage and make available appropriate skills training so that trainees are prepared to apply for subsequent independent support for their training or research program (e.g., an individual fellowship award, mentored career development award, or research project grant), as appropriate for their career stage.  In addition, past studies have shown that health professional trainees who train in programs with postdoctoral researchers who have intensive research backgrounds are more likely to apply for and receive subsequent research grant support.  Programs that emphasize research training for individuals with the MD or other health-professional degrees are therefore encouraged to develop ties to basic science departments and include trainees with research doctorates when this approach is consistent with the goals of the proposed training program.

Biomedical research and the resulting scientific knowledge are increasingly complex and multidisciplinary in nature. Training PDs/PIs are encouraged to develop institutional training programs that will expose trainees to a diversity of scientific approaches, systems for study, research approaches, and tools and technologies. Consideration of team-based research approaches may also be warranted depending upon the goals of the proposed training program.

Within the framework of the NRSA program’s longstanding commitment to excellence and the projected need for investigators in particular areas of research, attention must be given to recruiting trainees from racial or ethnic groups underrepresented in the biomedical, behavioral and clinical sciences, individuals with disabilities, and individuals from disadvantaged backgrounds.

The career outcomes of individuals supported by NRSA training programs include both research-intensive careers in academia and industry and research-related careers in various sectors, e.g., academic institutions, government agencies, for-profit businesses, and private foundations. Training programs should make available structured, career development advising and learning opportunities (e.g., workshops, discussions, Individual Development Plans). Through such opportunities, trainees are expected to obtain a working knowledge of various potential career paths that would make strong use of the knowledge and skills gained during research training and the steps required to transition successfully to the next stage of their chosen career.

General Information

Document Type: Grants Notice
Funding Opportunity Number: PA-16-152
Funding Opportunity Title: Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Environment
Food and Nutrition
Health
Income Security and Social Services
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.113 — Environmental Health
93.172 — Human Genome Research
93.173 — Research Related to Deafness and Communication Disorders
93.213 — Research and Training in Complementary and Integrative Health
93.242 — Mental Health Research Grants
93.273 — Alcohol Research Programs
93.279 — Drug Abuse and Addiction Research Programs
93.286 — Discovery and Applied Research for Technological Innovations to Improve Human Health
93.351 — Research Infrastructure Programs
93.361 — Nursing Research
93.398 — Cancer Research Manpower
93.837 — Cardiovascular Diseases Research
93.838 — Lung Diseases Research
93.839 — Blood Diseases and Resources Research
93.846 — Arthritis, Musculoskeletal and Skin Diseases Research
93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research
93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders
93.855 — Allergy and Infectious Diseases Research
93.856 — Microbiology and Infectious Diseases Research
93.859 — Biomedical Research and Research Training
93.865 — Child Health and Human Development Extramural Research
93.866 — Aging Research
93.867 — Vision Research
Cost Sharing or Matching Requirement: No
Posted Date: Mar 25, 2016
Last Updated Date: Mar 25, 2016
Original Closing Date for Applications: Jan 07, 2019  
Current Closing Date for Applications: Jan 07, 2019  
Archive Date: Feb 07, 2019
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants:
Public and State controlled institutions of higher education
Private institutions of higher education
Native American tribal governments (Federally recognized)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Additional Information

Agency Name: National Institutes of Health
Description: The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible, domestic institutions to enhance predoctoral and postdoctoral research training, including short-term research training, and help ensure that a diverse and highly trained workforce is available to meet the needs of the Nations biomedical, behavioral, and clinical research agenda. Research training programs will incorporate didactic, research, and career development elements to prepare individuals for careers that will have a significant impact on the health-related research needs of the Nation. Programs proposing only short-term research training should not apply to this announcement, but rather to the Kirschstein-NRSA Short-Term Institutional Research Training Grant Program (T35) exclusively reserved for predoctoral, short-term research training (see PA-16-151).
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PA-16-152.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Advertisements

NeuroNEXT Clinical Trials (U01)

PAR-16-155
NeuroNEXT Clinical Trials (U01)
Department of Health and Human Services
National Institutes of Health

Scope of the Program

This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies.  Applications for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it is expected to be of benefit in ameliorating a specific aspect of the disease. Neurologic diseases chosen for study must fall within the primary responsibility of NINDS (http://www.ninds.nih.gov/disorders/disorder_index.htm).

Examples of appropriate studies under this FOA include, but are not limited to, those designed to:

  • Evaluate and optimize the dose, formulation, safety, tolerability or pharmacokinetics of an intervention in the target population.
  • Evaluate whether an intervention produces sufficient evidence of short-term activity (e.g., biomarker activity, pharmacodynamic response, target engagement, dose-response trends) in a human “proof of concept” trial.
  • Select or rank the best of two or more potential interventions or dosing regimens to be evaluated in a subsequent trial, based on tolerability, safety data, biological activity, or preliminary clinical efficacy (e.g., futility trials).
  • Evaluate biological activity relative to clinical endpoints.
  • For medical devices, in addition to providing initial clinical safety data, appropriate studies are those that inform the next phase of development, usually by finalizing the device design, establishing operator technique, and/or finalizing the choice of study endpoints for the design of a pivotal clinical trial.

Studies in stroke prevention, treatment and/or recovery are not appropriate for inclusion in  NeuroNEXT. All multi-site stroke studies will be conducted in the NINDS-funded stroke trials network (http://www.ninds.nih.gov/research/clinical_research/NINDS_stroke_trials_network.htm).

neurology

 

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-16-155
Funding Opportunity Title: NeuroNEXT Clinical Trials (U01)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders
Cost Sharing or Matching Requirement: No
Posted Date: Mar 28, 2016
Last Updated Date: Mar 28, 2016
Original Closing Date for Applications: Aug 03, 2017  
Current Closing Date for Applications: Aug 03, 2017  
Archive Date: Sep 03, 2017
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants:
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
For profit organizations other than small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
State governments
City or township governments
Public housing authorities/Indian housing authorities
Special district governments
County governments
Private institutions of higher education
Small businesses
Native American tribal governments (Federally recognized)
Independent school districts
Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS’ strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-16-155.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Adult Maturational Changes and Dysfunctions in Emotion Regulation (R01)

RFA-MH-17-405
Adult Maturational Changes and Dysfunctions in Emotion Regulation (R01)
Department of Health and Human Services
National Institutes of Health

brain

Background

Research suggests that, for many adults, normal aging is associated with general trends toward improved emotion regulation (e.g., as evidenced by increasing positive and decreasing negative affect, greater emotional stability, higher life satisfaction, a “positivity effect” in information-processing).  As compared with younger adults, older adults often show superior emotion regulation capacities, employ different strategies for executive control of emotional information, and recruit different neural networks in performing affective tasks.  Such patterns have been variously hypothesized to stem from increased motivation to maintain emotional well-being, learning of more skillful and efficient emotion processing strategies, or compensatory adaptations to age-related brain changes. A number of hypotheses regarding the strategies older adults employ to regulate emotion and the neurobiological systems that support them remain untested.  There is also considerable evidence that men and women process emotions differently, though, to date, evidence is scarce regarding whether and how sex differences may be modulated during the aging process.

Not all adults demonstrate the positive emotion regulation profiles that characterize adaptive aging.  To date, there has been little mechanistic research focused on sources of individual variability in development and maturation of emotional regulatory functions. Mood and anxiety disorders are considered examples of affect dysregulation.  However, knowledge tends to be limited about the specific emotion processing deficits involved, and how these may change with maturation.  Few studies employing affective neuroscience methods have examined adult maturational processes relative to mental disorder.  There has been little scientific investigation of the extent to which adults with affective disorders manifest or fail to show the normative maturational shifts, or at what point(s) during the adult lifespan they may tend to traverse divergent emotion regulation trajectories.

In addition, significant gaps remain in our understanding of successful emotion regulation in adults aging without mental disorders.  It is paradoxical that, despite normative cognitive declines with age, many aspects of emotional function improve with age.  Though attributed to improved emotional regulatory strategies, such strategies frequently rely on the same cognitive control capacities that decline with aging.  Numerous questions remain regarding the role of cognitive control in adaptive emotional aging, alternative strategies that older adults might employ to regulate emotion, the cognitive processes that undergird those strategies, and the causes of individual variation in the ability to engage these strategies with advancing age.

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-MH-17-405
Funding Opportunity Title: Adult Maturational Changes and Dysfunctions in Emotion Regulation (R01)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.242 — Mental Health Research Grants
93.866 — Aging Research
Cost Sharing or Matching Requirement: No
Posted Date: Mar 29, 2016
Last Updated Date: Mar 29, 2016
Original Closing Date for Applications: Jul 22, 2016  
Current Closing Date for Applications: Jul 22, 2016  
Archive Date: Aug 22, 2016
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants:
State governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Independent school districts
For profit organizations other than small businesses
Public and State controlled institutions of higher education
Private institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Special district governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
County governments
Native American tribal organizations (other than Federally recognized tribal governments)
City or township governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: This funding opportunity announcement (FOA) invites applications for mechanistic research on how age- and sex-related changes in emotion processing develop over the adult life course and how these changes may interact with and inform the understanding of affective dysregulation in adult mental disorders and Alzheimer’s disease.In particular, research is sought that will leverage the already established normative backdrop of generally improved emotion regulation with aging, as well as research that will expand this evidence base.One aim is to clarify the trajectories of change in emotion processing and linked neurobiological and neurobehavioral factors in aging adults who experience mood and anxiety disorders.Equally important aims are to advance understanding of the factors involved in normative maturational shifts in these processes and of sources of individual variation therein, and to clarify how such shifts (or lack thereof) may relate to irregularities in the integrative neural-behavioral mechanisms of affect regulation seen in these adult mental disorders and in Alzheimer’s disease.It is anticipated that such studies may identify novel targets for mental health interventions or prevention efforts, or provide clues as to which available intervention strategies might be optimally applied to normalize emotion dysregulation or to strengthen emotional resilience at particular stages of the adult life cycle.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-405.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

PD-16-018Y Cybermanufacturing Systems – National Science Foundation

PD-16-018YNSFlogo
Cybermanufacturing Systems
National Science Foundation

The Cybermanufacturing Systems (CM) Program supports fundamental research to enable the evolution of a wide range of network-accessed manufacturing services that:

  • employ applications (or “apps”) that reside in the “cloud” and plug into an expansible, interactive architecture;
  • are broadly accessible, guarantee reliable execution and have capabilities that are transparent to users; and
  • are accessible at low cost to innovators and entrepreneurs, including both users and providers.

Research areas of interest include, but are not limited to, the following:

  • Frameworks for partitioning the mechanical design space to ensure tractability of design-to-manufacturing translation, possibly by part type or application domain;
  • Computer-Aided Design (CAD) engines that facilitate the restriction of design options, possibly by facilitating the creation of generic part designs that can be customized by entering a limited number of dimensional parameters;
  • Product- and domain-focused parametric design apps that connect to manufacturing resources and incorporate process constraints to enable part design and fabrication by users who lack detailed process knowledge;
  • Software systems for generating and verifying machine instructions and providing guidance in design for manufacturability;
  • Model-based process and machine controls that plug-and-play in a strongly integrated and networked environment;
  • Methods for selecting and efficiently allocating networked manufacturing resources;
  • Process and materials selection systems;
  • Methods for establishing and maintaining evidence-based certification and controlled visibility of explicit and implicit assumptions;
  • System architectures that are implementable using existing Internet protocols or that aim to identify the specific changes that are needed to existing Internet protocols to improve their effectiveness;
  • Software and protocols for promoting and accommodating user-developed, interoperating manufacturing apps, including hardware computing platforms, operating systems, and middleware; and
  • Methods for safeguarding the security and trustworthiness of cybermanufacturing system elements and integrating them to support end-to-end assurances.

Collaborations between engineering and computer science faculty are strongly encouraged, as are collaborations with software, networking, internet service and industrial companies, including the partner institutes of the National Network for Manufacturing Innovation (NNMI, http://manufacturing.gov/welcome.html) and their member companies.

General Information

Document Type: Grants Notice
Funding Opportunity Number: PD-16-018Y
Funding Opportunity Title: Cybermanufacturing Systems
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 10
CFDA Number(s): 47.041 — Engineering Grants
Cost Sharing or Matching Requirement: No
Posted Date: Mar 15, 2016
Last Updated Date: Mar 15, 2016
Original Closing Date for Applications: Proposals accepted anytime
Current Closing Date for Applications: Proposals accepted anytime
Archive Date:
Estimated Total Program Funding: $3,000,000
Award Ceiling: $600,000
Award Floor: $10,000
Link to Additional Information: NSF Program Desccription PD-16-018Y
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NSF grants.gov support grantsgovsupport@nsf.gov
If you have any problems linking to this funding announcement, please contact

Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01)

PAR-16-121
Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01)
Department of Health and Human ServicesSquare_TransparentBackground
National Institutes of Health

Background

Recent significant advances in genetics, physiology, and the pathogenesis of disease coupled with technological advances in areas such as bioinformatics, chemical biology, non-mammalian disease modeling, and protein engineering have provided a rich knowledge base and strong toolbox to identify and pursue new therapeutics with the goal of generating new molecular, microbial, and cellular therapies for the treatment of disease. Despite the availability of these approaches, we are facing an increased failure rate of potential therapeutics for reasons of both safety and lack of human efficacy.  A critical need exists to develop better strategies to validate and prioritize therapeutic leads based on their likelihood of success to safely alter disease progression and outcomes in humans.

Purpose

Projects submitted to this FOA should be directly focused on a therapeutic lead that will modulate a health-related outcome of interest to the NIDDK. Prior to submitting an application, investigators are strongly encouraged to contact the Scientific/Research Contact for this FOA to discuss the appropriateness of the proposed research to this FOA. Information concerning programmatic areas at NIDDK is available at: www.niddk.nih.gov/research-funding/research-programs/Pages/default.aspx. Projects in areas that are primarily within the missions of other Institutes or Centers (ICs) of the NIH are not appropriate for this FOA and will not be supported.

Staging of Therapeutic Discovery and Validation

The process of identifying and validating therapeutic leads such as small molecules or non-viral biologics for the treatment of human disease begins with a hypothesis and can be viewed as progressing along a continuum of increasing confidence leading to widespread acceptance of its use in people (www.niddk.nih.gov/research-funding/process/translational-research-therapeutic-discovery-development/Pages/default.aspx). For the purposes of this FOA, these stages are defined as:

Identification of therapeutic leads: This may occur through a variety of approaches and stages such as identifying targets, screening compound libraries, or constructing prototype non-viral biologics with preliminary evidence that they may significantly impact a disease process.

Early-stage preclinical validation: Pre-clinical hypothesis testing to generate data that, over time, increases confidence that manipulation of disease processes via a specific therapeutic strategy may be clinically efficacious and safe. This process occurs prior to clinical testing of a new therapeutic, and ideally should include the use of human-derived data, tissues, cells, and systems.

Clinical validation: Studies conducted in human patient populations to fully understand the efficacy and safety profiles of a therapeutic agent. True validation of a therapeutic agent may take decades of post-regulatory approval data accumulation.

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-16-121
Funding Opportunity Title: Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Food and Nutrition
Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research
Cost Sharing or Matching Requirement: No
Posted Date: Mar 09, 2016
Last Updated Date: Mar 09, 2016
Original Closing Date for Applications: May 07, 2019  
Current Closing Date for Applications: May 07, 2019  
Archive Date: Jun 07, 2019
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants:
Small businesses
City or township governments
Native American tribal organizations (other than Federally recognized tribal governments)
Private institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
County governments
Special district governments
Public housing authorities/Indian housing authorities
Independent school districts
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
For profit organizations other than small businesses
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal governments (Federally recognized)
State governments
Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: The overarching goal of this Funding Opportunity Announcement (FOA) is to translate basic science research into knowledge and tools that can be utilized to provide strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases, hematology, and specific aspects of cystic fibrosis. Additional information concerning programmatic areas at NIDDK is available at: http://www.niddk.nih.gov/research-funding/research-programs/Pages/default.aspx.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-16-121.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

The Application of Big Data Analytics to Drug Abuse Research (R01)

PA-16-119
The Application of Big Data Analytics to Drug Abuse Research (R01)
Department of Health and Human ServicesRx-Drugs
National Institutes of Health

Nature of the Research Opportunity

Big Data is used here to refer to computational analytic techniques able to recognize patterns in information which surpass the limits of human intuition.  This FOA focuses on applying Big Data analytics to reveal deeper or novel insights into the biological and behavioral processes associated with substance abuse and its treatment, and the relationships among them.   This FOA does not seek applications that propose to perform secondary analyses of data without using Big Data analytics (e.g. this FOA does not seek applications re-applying traditional methods to ascertain un-analyzed distinctions between study subpopulations) and applicants may consider submitting these applications to PA-13-080.  This FOA also is intended to distinguish itself from PA-13-080 in that the computational tools (e.g. aggregated datasets, standards, analytic software) developed to answer new scientific questions are able to be applied again to future research studies acquiring similar types of data, such that the end result of these funded grants increase the computational armamentarium available to addiction research.

Background

National investments in basic research, including President Obama’s BRAIN and Precision Medicine Initiatives, are poised to accelerate discoveries in neuroscience, genetics, and health services research.  In addition, a shift in culture, driven by the NIH Big Data to Knowledge Initiative, is promoting open access and data sharing to allow diverse data sets to be broadly accessible to researchers. Advances in information technologies and analytics capabilities are producing extraordinary capacity to integrate and analyze these data and enable novel research into the complexity of disorders such as drug abuse and addiction that are driven by the dynamic interactions of diverse biological, social, organizational, environmental, and behavioral mediators.   The result is a new, data-intensive era of research characterized by a heretofore unseen influx of data presenting new computational challenges which delay important discoveries due to bottlenecks in data analysis.  Big Data analytics provides new opportunities to maximize the value of research results by providing researchers the ability to analyze huge amounts of data in new ways – turning vast datasets of complex information into knowledge.

General Information

Document Type: Grants Notice
Funding Opportunity Number: PA-16-119
Funding Opportunity Title: The Application of Big Data Analytics to Drug Abuse Research (R01)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.279 — Drug Abuse and Addiction Research Programs
Cost Sharing or Matching Requirement: No
Posted Date: Mar 09, 2016
Last Updated Date: Mar 09, 2016
Original Closing Date for Applications: May 07, 2019  
Current Closing Date for Applications: May 07, 2019  
Archive Date: Jun 07, 2019
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants:
Special district governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public housing authorities/Indian housing authorities
For profit organizations other than small businesses
Independent school districts
Public and State controlled institutions of higher education
City or township governments
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Private institutions of higher education
Native American tribal governments (Federally recognized)
State governments
County governments
Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this FOA is to encourage the application of Big Data analytics to reveal deeper or novel insights into the biological and behavioral processes associated with substance abuse and addiction.NIDA recognizes that to accelerate progress toward understanding how the human brain and behavior is altered by chronic drug use and addiction, it is vital to develop more powerful analytical methods and visualization tools that can help capture the richness of data being generated from genetic, epigenetic, molecular, proteomic, metabolomic, brain-imaging, micro-electrode, behavioral, clinical, social, services, environmental studies as well as data generated from electronic health records.Applications for this FOA should develop and/or utilize computational approaches for analyzing large, complex datasets acquired from drug addiction research.The rapid increase of technologies to acquire unprecedented amounts of neurobiological and behavioral data, and an expanding capacity to store those data, results in great opportunity to bring to bear the power of the computational methods of Big Data analytics on drug abuse and addiction.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PA-16-119.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Network for Emergency Care Clinical Trials: Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) – Network Clinical Center (Hub) (U24)

RFA-NS-16-016
Network for Emergency Care Clinical Trials: Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) – Network Clinical Center (Hub) (U24)emergency medicine
Department of Health and Human Services
National Institutes of Health

Background

There is a clear public health imperative to stimulate and support research that improves care and clinical outcomes.  According to the Centers for Disease Control and Prevention (CDC), unintentional injuries are the leading cause of death for Americans under the age of 45.  In 2011, the most recent year with data published by the CDC, there were 136 million ED visits in the United States, accounting for about 4% of all health care spending.  Of the 136 million visits, 12%, or some 16 million, resulted in a hospital admission. About half of the top 10 reasons for presentation at an ED (i.e. chest pain, headache, cough, back symptoms, shortness of breath) are neurologic or heart, lung, blood (HLB) conditions and together these make up about 17% of all ED visits.

Clinical emergency care research covers all stages of the provision of emergency care, from pre-hospital emergency medical services to hospital EDs, trauma systems and emergency operative interventions. The principles of emergency care –making accurate and timely diagnoses and interventions– are independent of the disease, organ system and venue. The ED is the common entry portal for more than half of all hospitalized patients. Although dysfunction may start in one organ system, in a critical situation other organs can become rapidly involved, so successful care must address multiple systems. These characteristics of emergency care justify establishment of SIREN as a single, adaptable network able to support clinical trials in the multiple indications of neurology, cardiology, respiratory, hematology and trauma.

Research Objectives

SIREN will harness multidisciplinary emergency care expertise to provide scientific leadership and the infrastructure required to conduct large, simple, pragmatic clinical trials to advance knowledge of optimal patient management in the prehospital and ED setting.  In addition, the network may be called upon to include other venues where post emergency care is provided (such as critical care units, the operating room or other hospital settings) when required by the needs of peer-reviewed, meritorious clinical trials.

The Hubs will contribute to these objectives by exemplary execution of clinical trials, including rapid start up and enrollment, protection of human subjects, and provision of accurate data in a timely fashion. To facilitate trial performance, the Hubs will select and provide oversight and leadership to satellite clinical sites (“Spokes”).

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-NS-16-016
Funding Opportunity Title: Network for Emergency Care Clinical Trials: Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) – Network Clinical Center (Hub) (U24)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards: 10
CFDA Number(s): 93.837 — Cardiovascular Diseases Research
93.838 — Lung Diseases Research
93.839 — Blood Diseases and Resources Research
93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders
Cost Sharing or Matching Requirement: No
Posted Date: Mar 08, 2016
Last Updated Date: Mar 09, 2016
Original Closing Date for Applications: Jun 01, 2016  
Current Closing Date for Applications: Jun 01, 2016  
Archive Date: Jul 02, 2016
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants:
County governments
City or township governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
State governments
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Small businesses
Independent school districts
Special district governments
For profit organizations other than small businesses
Public and State controlled institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Private institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this funding opportunity announcement (FOA) is to invite applications for Clinical Centers (Hubs) in Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN).SIREN will enable conduct of high-quality, multi-site clinical trials to improve the outcomes for patients with neurologic, cardiac, respiratory, and hematologic, and trauma emergency events. SIREN will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and up to 10 clinical centers (Hubs). A Hub will typically be an academic center or tertiary referral center which will actively enroll patients into every clinical trial performed in SIREN, regardless of disease focus.A Hub will additionally provide scientific leadership and administrative oversight to its multiple satellite sites (“Spokes”).Together the Hub and Spokes will provide access to a large and varying patient population for clinical trials. SIREN will implement a total of at least four large (1,000 patient) simple, pragmatic clinical trials in the emergency department and pre-hospital settings. The clinical trials will be meritorious, peerreviewed projects which will be awarded under separate funding announcements.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-16-016.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster